Hangzhou AGS MedTech Co., Ltd. (SHA:688581)
China · Delayed Price · Currency is CNY 51.06
+0.15 (0.29%)
At close: Sep 4, 2026
Hangzhou AGS MedTech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,129 | 4,733 | 4,810 | 7,223 | - | - | |
Market Cap Growth | -30.84% | -1.60% | -33.41% | - | - | - |
Enterprise Value | 1,929 | 2,994 | 2,723 | 5,252 | - | - |
Last Close Price | 50.91 | 57.53 | 57.33 | 84.02 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.17 | 21.35 | 16.39 | 33.25 | - | - |
Forward PE | - | 13.09 | 15.01 | 29.08 | - | - |
PS Ratio | 6.96 | 7.97 | 7.56 | 14.20 | - | - |
PB Ratio | 1.62 | 1.88 | 2.01 | 3.27 | - | - |
P/TBV Ratio | 1.65 | 1.92 | 2.02 | 3.30 | - | - |
P/FCF Ratio | 27.89 | 53.94 | 18.07 | 42.52 | - | - |
P/OCF Ratio | 18.86 | 31.30 | 15.23 | 32.62 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.25 | 5.04 | 4.28 | 10.32 | - | - |
EV/EBITDA Ratio | 8.97 | 13.45 | 9.35 | 23.31 | - | - |
EV/EBIT Ratio | 9.54 | 14.21 | 9.65 | 24.01 | - | - |
EV/FCF Ratio | 13.03 | 34.13 | 10.23 | 30.92 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.02 | 0.00 | 0 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 0.33 | 0.17 | 0.01 | 0.00 | 0.01 | 0.02 |
Debt / FCF Ratio | 0.48 | 0.43 | 0.01 | 0.00 | 0.02 | 0.02 |
Net Debt / Equity Ratio | -0.86 | -0.77 | -0.74 | -0.92 | -0.70 | -0.75 |
Net Debt / EBITDA Ratio | -10.29 | -8.66 | -6.11 | -9.04 | -1.72 | -1.68 |
Net Debt / FCF Ratio | -14.86 | -21.98 | -6.69 | -11.99 | -2.77 | -1.98 |
Asset Turnover | 0.22 | 0.23 | 0.26 | 0.36 | 0.91 | 1.01 |
Inventory Turnover | 2.96 | 3.00 | 3.51 | 3.51 | 3.04 | 3.62 |
Quick Ratio | 13.24 | 13.34 | 12.90 | 17.37 | 3.18 | 3.19 |
Current Ratio | 13.67 | 13.79 | 13.34 | 17.78 | 3.65 | 3.81 |
Return on Equity (ROE) | 8.57% | 9.01% | 12.74% | 16.78% | 44.40% | 42.94% |
Return on Assets (ROA) | 4.70% | 5.04% | 7.22% | 9.75% | 23.02% | 24.30% |
Return on Invested Capital (ROIC) | 35.08% | 29.57% | 61.13% | 131.83% | 143.69% | 158.42% |
Return on Capital Employed (ROCE) | 7.90% | 8.30% | 11.70% | 9.90% | 39.30% | 42.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.18% | 4.69% | 6.10% | 3.01% | - | - |
FCF Yield | 3.59% | 1.85% | 5.54% | 2.35% | - | - |
Dividend Yield | 2.03% | 1.81% | 2.40% | 1.23% | - | - |
Payout Ratio | 91.14% | 50.15% | 28.40% | 20.25% | 24.80% | 46.80% |
Buyback Yield / Dilution | 0.30% | 0.13% | -11.02% | -19.46% | 0.00% | - |
Total Shareholder Return | 2.33% | 1.94% | -8.63% | -18.23% | - | - |